Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer

doi:10.2147/OTT.S230406

科研成果详情

题名	Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer
作者	Su, Meng 1; Gao, Ya 1; Ye, Xuxue 1; Zhou, Qingyu 1; Zhao, Lihao1; Cai, Xiaona2; Chen, Didi1; Su, Huafang1; Zhang, Xiaohua 3; Xie, Congying1
发表日期	2019
发表期刊	ONCOTARGETS AND THERAPY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	cervix carcinoma YN968D1 antiangiogenesis drug efficacy safety
其他关键词	ENDOTHELIAL GROWTH-FACTOR ; PHASE-II TRIAL ; HEPATOCELLULAR-CARCINOMA ; GASTRIC-CANCER ; SOLID TUMORS ; CHEMOTHERAPY ; BEVACIZUMAB ; EFFICACY ; YN968D1 ; CARBOPLATIN
摘要	Purpose: Apatinib is effective and safe for several advanced or metastatic cancers, but its therapeutic value in cervical cancer is still unknown. The aim of the study was to assess the therapeutic value of apatinib in patients with chemo-refractory advanced cervical cancer. Patients and methods: This was a retrospective study of patients with advanced cervical cancer treated with apatinib between April 2015 and December 2018 at the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Patients had to have failed at least 2 lines of chemotherapy prior to receiving apatinib. The clinical tumor response was evaluated after 4 weeks of apatinib treatment, and then every 8 weeks (two cycles). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events were evaluated. Results: Twenty-five patients were included in this study. The median PFS was 5.8 months (95% CI, 4.65-6.95), and the median OS was 12.2 months (95% CI, 8.99-15.41). ORR was 48% and DCR was 96%. Complete response was not observed. The most common adverse events in this study (all grades) were hand-foot syndrome (48%), hypertension (20%), and mouth mucositis (20%). Conclusion: Apatinib monotherapy showed good therapeutic value with tolerable adverse events for patients with chemo-refractory advanced cervical cancer.
资助项目	Wenzhou Municipal Science and Technology Bureau [2018H0004]
出版者	DOVE MEDICAL PRESS LTD
出版地	ALBANY
ISSN	1178-6930
卷号	12 页码:9707-9713
DOI	10.2147/OTT.S230406
页数	7
WOS类目	Biotechnology & Applied Microbiology ; Oncology
WOS研究方向	Biotechnology & Applied Microbiology ; Oncology
WOS记录号	WOS:000496427000001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	32009803
PMC记录号	PMC6859957
SCOPUSEID	2-s2.0-85075335136
通讯作者地址	[Xie, Congying]Department of Radiotherapy and Chemotherapy,The First Affiliated Hospital of Wenzhou Medical University,No. 2 Fuxue Street,Wenzhou,325000,China
Scopus学科分类	Oncology;Pharmacology (medical)
引用统计	被引频次：6[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/14160
专题	附属第一医院第二临床医学院、附属第二医院、育英儿童医院第二临床医学院、附属第二医院、育英儿童医院_影像医学与核医学_超声科
通讯作者	Xie, Congying
作者单位	1.Department of Radiotherapy and Chemotherapy,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 2.Derpartment of Ultrasonography,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 3.Department of Thyroid and Breast Surgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China
第一作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
通讯作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Su, Meng,Gao, Ya,Ye, Xuxue,et al. Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer[J]. ONCOTARGETS AND THERAPY,2019,12:9707-9713.
APA	Su, Meng., Gao, Ya., Ye, Xuxue., Zhou, Qingyu., Zhao, Lihao., ... & Xie, Congying. (2019). Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer. ONCOTARGETS AND THERAPY, 12, 9707-9713.
MLA	Su, Meng,et al."Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer".ONCOTARGETS AND THERAPY 12(2019):9707-9713.